Modalis Therapeutics Corporation
Stock Price Chart
2026/08/14 UpdatedPrice Trend
2026/08/14 UpdatedPrice & Trading Details
2026/08/14 UpdatedPRICE
TRADING
Financial Performance
2026/08/09 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | |
|---|---|
| Income Statement | |
| Revenue | ¥41M |
| Gross Profit | - |
| Operating Income | -¥2,063M |
| Pretax Income | -¥2,702M |
| Net Income | -¥2,703M |
| EPS | -¥92.85 |
| Operating Margin | -5,094.31% |
| Balance Sheet | |
| Total Assets | ¥3,130M |
| Total Equity | ¥2,941M |
| Total Liabilities | ¥189M |
| Cash | ¥2,933M |
| Interest-bearing Debt | ¥0M |
| Equity Ratio | 93.97% |
| D/E Ratio | 0.00 |
| Cash Flow | |
| Operating CF | -¥1,896M |
| Investing CF | -¥186M |
| Financing CF | ¥64M |
| Free CF | -¥2,093M |
| Efficiency | |
| ROE | -91.89% |
| ROA | -86.35% |
Latest IR Information
-
[Modalis] 2026 December Term Interim Period Financial Results Briefing Materials | Including Revisions
In the second quarter of the 2026 fiscal year, cash position improved while liabilities increased, with a policy to continue R&D investments. The financial statements show changes in current assets, current liabilities, and net assets, with trends in equity ratio...
Read more -
Interim Financial Results for the Fiscal Year Ending December 2026
Interim financial results for the six months ended December 2026 have been disclosed. Includes key indicators such as consolidated net sales and net income, financial position, dividend information, and cash flow, with details on performance and financial status for the...
Read more -
[Modalis] 2026 Q2 Financial Results Briefing Document
A financial results document that discloses trends in revenue and profit. While many figures are not disclosed, development codes such as MDL-101 and clinical progress are indicated, suggesting future business outlook and the direction of mid-term plans.
Read more -
Modalis Corporation 2026 Fiscal Year Interim Earnings Summary
Discloses interim results for the fiscal year ending December 2026. Provides key indicators such as net sales, operating income, and net income, along with segment trends, changes in financial position, and cash flow status. Also includes guidance for the next...
Read more -
Notice Regarding Recognition of Non-Operating Income and Special Profit
Notice regarding recognition of non-operating income and special profit, including foreign exchange effects. The main content explains the recognition status of items arising from foreign exchange gains/losses and other special items, and the outlook for future impact.
Read more
Latest News (5 items)
Company Information
About
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. The company is developing therapies for genetic diseases using its proprietary CRISPR-GNDM an epigenome editing technology that combines dCas9. It also develops various therapeutics for muscle disorders, cardiomyopathy, and CNS disorders. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019. Modalis Therapeutics Corporation was incorporated in 2016 and is headquartered in Chuo, Japan.
